Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from 91av
Explore the latest news, articles and features
Life
Extinct relative of koalas discovered in Western Australia
News
Physics
The 50-year quest to create a quantum spin liquid may finally be over
Features
Technology
Backlash builds over NHS plan to hide source code from AI hacking risk
News
Health
Hantavirus: Where has the deadly cruise ship outbreak come from?
News
Popular articles
Trending 91av articles
1
Woman in cancer remission without treatment in highly unusual case
2
Man destined to get Alzheimer’s saved by accidental heat therapy
3
Extinct relative of koalas discovered in Western Australia
4
We have figured out a new way to send messages into the past
5
The 50-year quest to create a quantum spin liquid may finally be over
6
A lost ancient script reveals how writing as we know it really began
7
Prebiotic chewing gum could be helpful for gum disease
8
Hantavirus: Where has the deadly cruise ship outbreak come from?
9
We may finally have a cure for many different autoimmune conditions
10
Why the keto diet could be a revolutionary way to treat mental illness
